Sign in
CompletedPhase 2

Maternal Buprenorphine-naloxone Treatment and the Infant

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
42 people enrolled
Started
1 Jun 2018
Ended
15 Dec 2023
Type of study
Interventional
Treatments tested
  • fetal monitoring
  • Buprenorphine Naloxone
Record updated
26 February 2024

Who can take part

Age
18 years to 44 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Current opioid use disorder (OUD) as defined by DSM V criteria
  • singleton pregnancies, generally uncomplicated by conditions that jeopardize pregnancy outcome
  • Gestation less than 24 weeks

Who cannot take part

  • Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery
  • Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension
  • Alcohol use disorder per DSM V criteria (see ascertainment methods below)
  • Evidence of fetal malformation detected by prenatal ultrasound
  • Significant maternal psychopathology that would preclude informed consent
  • Women stable on methadone maintenance (defined as more than 3 consecutive days of dosing)
  • Women coming to treatment reporting "street" methadone use (for more than 3 consecutive days
  • Women not planning to receive obstetric care at the Center for Addiction and Pregnancy; - Women not planning to deliver their infants at Johns Hopkins Bayview Medical center
  • Women planning for adoption of their infant

Where in United States

  • Johns Hopkins Bayview Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

The purpose of this mechanistic study is to evaluate the effects that maternal buprenorphine-naloxone maintenance have on the neurobehavioral development of the fetus and infant. To accomplish this, the investigators will study a sample of 120 opioid dependent pregnant women that will receive buprenorphine-naloxone as part of substance abuse treatment at a comprehensive care treatment facility for pregnant and parenting women with substance use disorders. Fetal neurobehavior and maternal physiology will be assessed, via an established maternal-fetal data acquisition system, at 4 points during gestation: 24, 28, 32 and 36 weeks. Infant birth parameters and Neonatal Abstinence Syndrome (NAS) spectrum display will be evaluated at birth, and infant neurodevelopment will be assessed during the first month of life.

The group in the trial

  • Buprenorphine-naloxone treatedTreatment being tested

    Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy

    Treatment: fetal monitoring and Buprenorphine Naloxone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Maternal Buprenorphine-naloxone Treatment During the Perinatal Period: Fetal and Infant Effects
Record updated
26 February 2024